Here’s a startling fact: Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, even when caught early and localized. But what if a simple biomarker could predict who’s most likely to survive and respond to treatment? Enter the NEOLAP trial (AIO-PAK-0113), a groundbreaking study that’s shedding light on this very question. This phase II trial explored whether induction chemotherapy followed by surgery could improve the odds of a margin-negative (R0) resection—the gold standard for survival. Yet, despite advances in treatment, outcomes remain frustratingly inconsistent. And this is the part most people miss: without reliable biomarkers, doctors are often left in the dark when it comes to predicting who will benefit most from these aggressive therapies.
That’s where growth differentiation factor-15 (GDF-15) comes in. The NEOLAP trial provided a unique opportunity to investigate GDF-15 as a potential game-changer in localized, non-metastatic PDAC. Published in ESMO Gastrointestinal Oncology in 2026, this translational analysis dove deep into GDF-15’s role as both a prognostic and predictive biomarker. But here’s where it gets controversial: while GDF-15 is linked to poor outcomes in cancer, it’s not just a marker of tumor size. Instead, it acts as a stress-induced mediator, influencing how the immune system and tumor microenvironment interact. Could this make it a double-edged sword—both a predictor of survival and a target for therapy?
GDF-15, also known as macrophage inhibitory cytokine-1, is part of the transforming growth factor-β superfamily. Normally, it’s barely detectable in healthy individuals, but its levels spike in response to cellular stress, including inflammation, tissue damage, metabolic imbalances, and cancer. In PDAC, elevated GDF-15 levels have been tied to worse outcomes, but its exact role has remained elusive—until now.
The NEOLAP trial enrolled 165 patients with locally advanced, non-metastatic PDAC, treating them with induction chemotherapy (nab-paclitaxel plus gemcitabine, with or without FOLFIRINOX) before surgery. Researchers measured circulating GDF-15 (cGDF-15) at baseline and after 16 weeks, while also assessing tumor GDF-15 (tGDF-15) expression via immunohistochemistry. The results? Patients with low baseline cGDF-15 (≤0.8 ng/ml) lived significantly longer (median OS: 21.9 months) compared to those with higher levels (12.7 months). Even more striking, low cGDF-15 predicted a higher chance of achieving R0 resection (36.5% vs. 13.9%).
But wait—there’s more. During chemotherapy, cGDF-15 levels rose dramatically, especially in patients on platinum-based regimens. This increase wasn’t tied to tumor response or CA 19-9 levels, suggesting GDF-15 plays a unique role in treatment response and disease progression. Tumor GDF-15 expression also increased post-chemotherapy, mirroring circulating levels. Is this a sign that GDF-15 is more than just a biomarker—could it be a key player in how PDAC evolves under treatment?
These findings position GDF-15 as a powerful tool for predicting survival and surgical success in localized PDAC. But they also raise provocative questions: Should we be targeting GDF-15 directly in future therapies? Could its role in cancer-associated cachexia make it a dual-purpose biomarker and therapeutic target? The NEOLAP trial has opened the door to these possibilities, but the debate is far from over.
What do you think? Is GDF-15 the missing piece in PDAC treatment, or just another biomarker in a long list of contenders? Share your thoughts in the comments—let’s keep the conversation going.
For the full article, dive into the details here: https://www.esmogastro.org/article/S2949-8198(25)00143-8/fulltext.
